In Vitro Modulation of Peroxisome Proliferator-activated Receptor-γ and Its Genes by C-Reactive Protein. Role of Atorvastatin

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 154-161

  Mahajan, Nitin ^a   Dhawan, Veena ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

C reactive protein; LXR ; MMP 9; PPAR

Indexed keywords

ATORVASTATIN; BETA ACTIN; C REACTIVE PROTEIN; GELATINASE B; LIVER X RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ATHEROSCLEROSIS; BASE SEQUENCE; C-REACTIVE PROTEIN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DNA PRIMERS; GENE EXPRESSION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 9; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77953504487     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.04.005     Document Type: Article

References (39)

1. Packard R.S., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
2. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
3. Castrillo A., Tontonz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 2004, 20:455-480.
4. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008, 75:346-359.
5. Zelcer N., Tontonoz P. Liver X receptor as integrator of metabolic and inflammatory signalling. J Clin Invest 2006, 116:607-614.
6. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEJM 2002, 347:1557-1565.
7. Cermak J., Key N.S., Bach R.R. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513-520.
8. Williams T.N., Zhang C.X., Game B.A. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc(gamma)RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004, 24:61-66.
9. Abe N., Osanai T., Fujiwara T., et al. C-reactive protein-induced up-regulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 2006, 78:1021-1028.
10. Nabata A., Kuroki M., Ueba H., et al. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque. Atherosclerosis 2008, 196:129-135.
11. Mahajan N., Bahl A., Dhawan V. C-reactive protein (CRP) up-regulates the expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of Atorvastatin. Int J Cardiol 2009, 10.1016/j.ijcard.2009.01.008.
12. Rikitake Y., Kawashima S., Takeshita S., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001, 154:87-96.
13. Laufs U., La Fata V., Plutzky J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
14. Blum A, Shamburek R. Pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis doi:10.1016/j.atherosclerosis.2008.08.022.
15. Paoletti R., Bolego C., Cignarella A. Lipid and non-lipid effects of statins. Hand Exp Pharmacol 2005, 170:359-382.
16. Almuti K., Rimawi R., Spevack D., et al. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006, 109:7-15.
17. Ichida Y., Hasegawa G., Fukui M., et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 2006, 76:34-39.
18. Grip O., Janciauskiene S., Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002, 51:58-62.
19. Kaul D., Baba M.I. Genomic effect of vitamin 'C' and statins within human mononuclear cells involved in atherogenic process. Eur J Clin Nutr 2005, 59:978-981.
20. Centrillo A., Joseph S.B., Marathon C., et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. JBC 2003, 278:10443-10449.
21. Sharma I., Dhawan V., Mahajan N., et al. In vitro effects of atorvastatin on LPS-induced gene expression in endometriotic stromal cells. Fertil Steril 2009, 10.1016/j.fertnstert.2009.10.003.
22. Mahajan N., Dhawan V., Sharma G., et al. Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolemic hypertensive sera and modulatory effects of green tea polyphenols. J Hum Hypert 2008, 22:141-143.
23. Duval C., Chinetti G., Trottein F. The role of PPARs in atherosclerosis. Trends Mol Med 2002, 8:422-430.
24. Li A.C., Palinski W. Peroxisome proliferator activated receptor. How their effects on macrophages can lead to the development of new drug therapy against atherosclerosis. Anal Rev Pharmacol Toxicol 2006, 46:1-39.
25. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator activated receptor in inflammation control. J Endocrinol 2001, 169:453-459.
26. Clyne B., Olshaker J.S. The C-reactive protein. J Emerg Med 1999, 17:1019-1025.
27. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. PNAS 1998, 75:7614-7619.
28. Inoue H., Tadashi T., Umesono K. Feedback control of cyclooxygenase-2 expression through PPAR-γ. J Biol Chem 2000, 275:28028-28032.
29. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently co-localizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18:1386-1392.
30. Burke A.P., Kolodgie D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Bio 2004, 24:1266-1271.
31. Baba M.I., Kaul D., Grover A. Importance of blood cellular genomic profile in coronary heart disease. J Biomed Sci 2006, 13:17-26.
32. Qiu G., Hill J.S. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res 2007, 48:2112-2122.
33. Hu W.L., Qian S.B., Li J.J. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007, 40:201-206.
34. Kibayashi E., Urakaze M., Kobashi C., et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci 2005, 108:515-521.
35. Hiraoka M., Nitta N., Nagai M., et al. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase, but not ERK1/2-dependent pathway. Life Sci 2004, 75:1333-1341.
36. Masamura K., Oida K., Kanehara H. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003, 23:512-517.
37. Cilla D.D., Whitfield L.R., Gibson D.M., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996, 60:687-695.
38. Oktem M., Esinler I., Eroglu D., et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 2007, 22:1474-1480.
39. Degraeve F., Bolla M., Blaie S. Modulation of COX-2 Expression by statins in human aortic smooth muscle cells: involvement of geranylgeranylated proteins. JBC 2001, 276:46849-46855.